Amgen Inc.

(NASDAQ Global Select)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Bullish +75

Amgen Earnings Call Highlights Growth, Pipeline Momentum

Drug approval Earnings report Guidance raised AI-generated analysis

Amgen Inc (AMGN) reported strong third-quarter results with revenue rising 8% year-over-year to $10.4 billion, driven by a diverse portfolio where six key growth drivers accounted for over 70% of sales. The company highlighted robust cash generation, posting free cash flow of $3.7 billion in...

Bullish Signals

  • Q3 revenue hit $10.4B, up 8% YoY.
  • Free cash flow reached $3.7B in Q3.
  • Raised 2026 guidance to $38.9-$39.7B.
  • Repatha sales climbed 37% to $1.1B.
  • EVENITY revenue rose 39% to $751M.

Bearish Signals

  • TEPEZZA sales declined 6% due to prior-year inventory build.
  • Q4 expenses rise; $2B-$2.1B pressure expected in 2026.
  • Sjogren's results not directly applicable to symptomatic study.
  • IMDELLTRA adoption faces challenges outside specialist centers.
  • MariTide reimbursement difficult outside U.S. due to consumer-driven decisions.
2
Bullish +75

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

AI-generated analysis

Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. This approval is based...

Bullish Signals

  • EC approved IMDYLLTRA® for ES-SCLC post-chemotherapy.
  • DeLLphi-304 trial cut death risk by 40%.
  • Median survival extended to 13.6 vs 8.3 months.
  • First T-cell engager therapy approved in Europe.
  • Targets DLL3 protein in up to 96% of patients.

Bearish Signals

  • CRS occurred in 56.7% of patients; fatal cases reported.
  • Neurologic toxicity (ICANS) affected 65%; one fatal case.
  • Treatment discontinuation required for 0.6% due to CRS.
  • Serious infections including fatal cases reported with IMDYLLTRA.
  • Elevated liver enzymes in 39-43%; Grade 3/4 events rare.
  • Cytopenias common: neutrophils down 16%, platelets down 30%.
  • Requires specialized facility for monitoring severe reactions.
  • Patients must stay near facility 48 hours post-infusion.
  • Hypersensitivity reactions including bronchospasm reported.
3
Bullish +57

Amgen Earnings Call Highlights Growth Engines, Tax Risk

AI-generated analysis

Amgen Inc (AMGN) reported first-quarter earnings and provided an upgraded forward outlook, driven by strong performance in its core growth franchises despite headwinds from legacy product decline and regulatory uncertainties. Total product sales grew 4% year over year, totaling approximately $13.7 billion, fueled primarily by...

Bullish Signals

  • Overall sales grew 4% driven by high-growth franchises.
  • Six drivers delivered 70% of sales with 24% YoY growth.
  • 16 products achieved double-digit growth and 17 exceeded $1B annually.
  • Repatha sales surged 34% to $876 million in Q1.
  • Evenity grew 27% to $562 million holding 65% U.S. bone market.
  • Rare disease portfolio expanded 25% to $1.2 billion total.
  • Innovative oncology revenue rose 25% reaching $1.8 billion.
  • Biosimilar sales climbed 14% totaling $835 million including PABLUE.
  • 2026 guidance upgraded with EPS target of $21.70–$23.10.
  • Non-GAAP margin stayed robust at 45%.
  • Free cash flow generated was $1.5 billion in the quarter.

Bearish Signals

  • Legacy osteoporosis sales dropped 32% to $1.1 billion amid lost exclusivity.
  • Biosimilar competition threatens accelerated revenue decline through 2026.
  • FDA proposed withdrawal of Tabneos approval causing regulatory friction.
  • Blincyto subcutaneous and SLE trials paused due to inflammatory events.
  • AMG 193 development discontinued despite pipeline investment risks.
  • Draft IRS Notice challenges profit allocations for tax years 2016–2018.
  • Non-GAAP cost of sales rose to 19.5% with no near-term relief.
4
Bullish +65

Amgen stock in focus as company raises 2026 outlook

Drug pricing Earnings report Guidance raised AI-generated analysis

Amgen reported third-quarter 2026 results on Tuesday, November 3, after the U.S. market close, raising its full-year 2026 outlook following a strong performance in newer therapies. The company's revenue increased 8% year over year to $10.4 billion, driven by significant growth in its obesity and...

Bullish Signals

  • Raised FY2026 revenue guidance to $38.9B–$39.7B following strong Q3 performance.

Bearish Signals

  • Prolia/XGEVA dropped 45%/47% due to biosimilar competition.
  • Enbrel price fell 14% under Inflation Reduction Act.
  • Free cash flow declined to $3.7B from $4.2B.
5
Bullish +75

Amgen wins Sjogren's trial as Jefferies raises target for Amgen stock

Clinical trial results Drug approval Earnings report AI-generated analysis

Amgen Inc. reported a positive Phase 3 clinical trial result for its drug dazodalibep in systemic Sjogren's disease, marking a significant milestone for the biopharmaceutical company. The OASIZ 301 study met its primary endpoint at Week 48, demonstrating early improvement in disease activity measures that...

Bullish Signals

  • OASIZ 301 trial met primary endpoint for dazodalibep in Sjogren's disease.

Bearish Signals

  • Analysts view stock as fairly valued rather than overvalued.
  • Average target of USD 381.32 is below Jefferies' new target.
  • Phase 3 study OASIZ 303 remains pending completion in Q4 2026.
6
Bullish +75

Amgen stock rises 4.34 percent as trial data lift pipeline hopes

Clinical trial results Earnings report AI-generated analysis

Amgen Inc. shares rose 4.34% to close at $410.24 on September 22, 2026, driven by positive Phase 3 trial data for its drug candidate dazodalibep in Sjogren's disease. The OASIZ 301 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the...

Bullish Signals

  • Stock rose 4.34% to $410.24 on positive dazodalibep trial data.
  • Revenue hit $10.05B and EPS of $6.29, beating estimates by $0.67.
  • Revenue grew 9.5% year-over-year showing strong top-line performance.
  • Jefferies raised price target to $410 and peak dazodalibep sales to $4.5B.
  • OASIZ 301 Phase 3 met primary endpoint boosting pipeline outlook.

Bearish Signals

  • Dazodalibep regulatory filing depends on pending OASIZ-303 study results.
  • OASIZ-303 data not expected until Q4 2026, delaying commercial validation.
7
Bullish +75

Amgen Earnings Reaction Close To All-Time Highs!

AI-generated analysis

Amgen Inc. reported second-quarter 2012 financial results showing a 13% revenue increase to $4.5 billion and adjusted earnings rising 34% to $1.83 per share, significantly beating Thomson Reuters estimates of $1.54 EPS and $4.08 billion in revenue. The company raised its full-year 2012 guidance for...

Bullish Signals

  • Revenue grew 13% year-over-year to $4.5 billion.
  • Adjusted EPS surged 34% to $1.83.
  • Full-year revenue guidance raised to $16.9-$17.2 billion.
  • EPS guidance increased to $6.20-$6.35 range.
  • Product sales grew 8% across all therapeutic areas.

Bearish Signals

  • Significant long-term debt balance of approximately $22 billion.
8
Bullish +75

Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma

AI-generated analysis

A U.S. jury in Delaware has ruled that Amgen Inc. and its subsidiary Teneobio willfully infringed a key patent held by Harbour BioMed regarding antibody-discovery technology. The verdict, delivered following a trial that began June 8, 2026, found the defendants liable for patent infringement related...

Bullish Signals

  • $20.2M jury verdict validates core IP and technology platform.
  • Unanimous patent validity finding deters future infringement by competitors.
  • Willful infringement ruling could triple damages to $60.6M.
  • Victory reaffirms Harbour as true innovator in antibody discovery.
  • Delaware win sets precedent for small biotech firms.

Bearish Signals

  • Amgen pursuing legal issues post-trial, delaying resolution.
  • Damages could triple to $60.6 million.
  • Intensifying competition in multibillion-dollar antibody therapeutics market.
9
Bullish +72

Is Amgen Stock Priced Right Against Its Peers?

Financial outlook AI-generated analysis

Amgen (AMGN) is analyzed as a high-performing biotechnology peer that currently trades at a valuation discount compared to its largest competitor, Johnson & Johnson. Despite ranking second among six major drugmakers in both revenue growth and operating margins over the last four fiscal quarters, investors...

Bullish Signals

  • Ranked #2 among major drugmakers in revenue growth and operating margins.

Bearish Signals

  • P/E lower than peers despite superior growth and margins.
  • ENBREL sales fell 32.9% in 2025 to $2.23 billion.
  • Operating expenses expected to rise meaningfully in Q4 2026.
10
Bullish +72

Amgen stock last trades at USD 418.60 on September 28, 2026

Clinical trial results Drug approval AI-generated analysis

Amgen Inc. stock closed at USD 418.60 on September 28, 2026, representing a gain of 0.96% from the previous close of USD 414.61. The trading activity reflects ongoing investor interest in the biotechnology firm's pipeline developments and regulatory milestones. Significant progress was made for Amgen's...

Bullish Signals

  • FDA approved IMDELLTRA to reduce monitoring time to 6-8 hours.
  • DeLLphi-305 met primary endpoint with Imfinzi for overall survival.
  • Trial achieved secondary endpoints in 563 patients validating efficacy.
11
Bullish +60

AIA Group Ltd Grows Stake in Amgen Inc. $AMGN - Defense World

AI-generated analysis

AIA Group Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.2% during the first quarter, purchasing an additional 2,815 shares to own a total of 27,962 shares valued at $9.838 million. This filing highlights continued institutional interest alongside other hedge funds like Anfield Capital...

Bullish Signals

  • Amgen beat EPS estimates at $5.15 vs $4.77 consensus.
  • Revenue grew 5.8% YoY to $8.62 billion.
  • High ROE of 137.41% and net margin of 20.96%.
  • Freedom Capital upgraded rating to strong-buy.
  • Institutional investors increased stakes in the stock.

Bearish Signals

  • Wall Street Zen downgraded Amgen from buy to hold.
  • SVP Nancy A. Grygiel sold 15% of her holdings.
  • High P/E of 25.49 and PEG of 3.71.
12
Bullish +75

ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA(R) FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS

AI-generated analysis

Amgen Canada announced on April 7, 2026, that the governments of Ontario and Quebec have expanded public reimbursement for Repatha (evolocumab) to include eligible patients following an acute coronary syndrome (ACS). In Ontario, coverage under the Ontario Drug Benefit program now includes patients within 52...

Bullish Signals

  • Ontario expanded reimbursement for Repatha within 52 weeks of ACS.
  • Quebec became the first province to list Repatha on February 4.
  • Repatha addresses unmet needs as 42% of patients exceed LDL thresholds.
  • Globally, Repatha treats over 8.5M patients in more than 70 countries.

Bearish Signals

  • Reported hypersensitivity reactions may require discontinuation.
  • Limited safety data exist for pregnant or nursing women.
  • Infants exposed via breast milk face unknown risks.
  • Efficacy unestablished in pediatric patients under 10 years.
  • 42% of Canadian ACS patients remain above LDL-C targets.
13
Very Bullish +80

Amgen Announces Positive Topline Phase 3 Results For Subcutaneous Tepezza In Adults Living With Moderate-to-severe Active Thyroid Eye Disease

AI-generated analysis

Amgen announced positive topline results from a Phase 3 clinical trial for its drug TEPEZZA (teprotumumab-trbw) administered via subcutaneous injection using an on-body injector (OBI). The trial evaluated the efficacy and safety of this new delivery method in adults with moderate-to-severe active Thyroid Eye Disease...

Bullish Signals

  • Amgen positive Phase 3 top results for subcutaneous TEPEZZA.
  • 77% proptosis response rate vs 19.6% placebo at 24 weeks.
  • Subcutaneous form offers IV efficacy with convenient on-body injection.
  • Strong safety baseline from prior IV treatment up to 25,000 patients.
  • Mild-to-moderate injection site reactions did not require treatment interruption.

Bearish Signals

  • Visual function benefit at Week 24 was not statistically significant.
  • Tinnitus and ear discomfort risks limit eligibility in hearing impaired patients.
  • Injection site reactions may affect tolerance and compliance for subcutaneous use.
  • Extended infusion safety profiles remain unapproved and under investigation.
14
Bullish +75

Amgen (Nasdaq:AMGN) - Stock Analysis - Simply Wall St

Drug approval New drug indication AI-generated analysis

Amgen presented new clinical data at the American Heart Association Scientific Sessions 2026 supporting earlier use of its blockbuster drug Repatha for high-risk cardiovascular patients. The findings demonstrate that the therapy is highly cost-effective and beneficial for individuals without prior heart attacks or strokes, as...

Bullish Signals

  • Repatha data shows high cost-effectiveness for high-risk patients.
  • FDA/EC approvals expanded Repatha patient pool in Aug 2025.
  • Shares up 42.0% YTD as Repatha market grows.
15
Neutral +10

Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?

Earnings report Financial outlook Guidance raised AI-generated analysis

Amgen (AMGN) is preparing to report its third-quarter earnings on November 3, facing a potential profit squeeze driven by rising operating expenses and legacy drug erosion. The company posted a fifth consecutive EPS beat in the prior quarter with revenue of $10.05 billion, but analysts...

Bullish Signals

  • EPS beat fifth consecutive quarter at $6.29 vs $5.62 consensus.

Bearish Signals

  • Q3 EPS consensus dropped to $5.79 from $6.29.
  • CFO warns of meaningful sequential operating expense increase.
  • Legacy products eroding: Prolia -32%, XGEVA -34%.
  • Margins slipped 0.5pts; full-year guidance lowered to 45-46%.
  • $100M upfront payment booked to R&D expenses.
16
Bullish +68

Scotiabank raises target for Amgen stock from USD 450.00 to USD 500.00

Analyst upgrade Clinical trial results Dividend AI-generated analysis

Scotiabank analyst Louise Chen raised her price target for Amgen Inc. from USD 450.00 to USD 500.00, maintaining an outperform rating. This significant upward revision of 11.11 percent reflects the company's strong recent financial performance and positive pipeline developments, positioning the stock as a key...

Bullish Signals

  • Scotiabank raised price target to USD 500.00, outperform rating maintained.
  • Q2 revenue hit USD 10.05B, beating consensus by USD 620M.
  • Adjusted EPS of USD 6.29 significantly beat the USD 5.62 estimate.
  • Phase 3 OASIZ 301 study met primary endpoint in Sjogren's disease.
  • Declared quarterly dividend of USD 2.52 per share, yielding 2.50%.
17
Bullish +75

Amgen Stock Climbs on Rising Earnings Guidance and Dividend Strength

AI-generated analysis

Amgen's stock price surged on September 18, 2026, closing at $385.65 on Nasdaq, representing a gain of 1.55% from the previous session. This positive market reaction was driven primarily by the company's updated financial outlook and its commitment to shareholder returns through a robust dividend...

Bullish Signals

  • Stock surged 1.55% to $385.65 on Sept 18, 2026.
  • Management raised 2026 EPS guidance to $22.30-$23.50.
  • Offers strong 2.6% dividend yield with $10.08 annual payout.
18
Slightly Bullish +15

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained

AI-generated analysis

Wall Street analysts have issued fresh ratings on major biopharma stocks, with Jefferies initiating a Buy on Gilead Sciences and a Hold on Amgen, while JPMorgan maintained an Overweight rating on clinical-stage oncology firm Oric Pharmaceuticals. These moves reflect a nuanced market view where Gilead...

Bullish Signals

  • Clean IP runway with no major loss until 2036.
  • Gilead Q4 revenue $7.93B beat consensus of $7.85B.
  • Non-GAAP EPS $1.86 beat estimate of $1.85.
  • Descovy revenue surged 33% to $819 million in Q4.
  • Yeztugo adds commercial catalyst heading into 2026.
  • Low beta 0.37 and 2.2% dividend yield appeal investors.
  • Repatah revenue grew 44% to $870 million in Q4.
  • Amgen non-GAAP EPS $5.29 beat estimate of $4.83.
  • Rinzimetostat showed 55% response rate in prostate cancer trials.
  • Oric holds $392.3 million cash runway into late 2028.

Bearish Signals

  • Amgen trades above Jefferies' $350 target, limiting upside.
  • Biosimilar competition threatens Amgen's Prolia and XGEVA revenue.
  • Enbrel revenue dropped 48% to $532 million in Q4.
  • Amgen's MariTide Phase 3 obesity program faces competitive risks.
  • Oric has no revenue and carries substantial binary pipeline risk.
  • Negative 2026 Phase 3 results for Oric could severely punish stock.
  • Gilead cell therapy revenue fell 6% to $458 million in Q4.
19
Slightly Bullish +15

Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp

AI-generated analysis

Bank of New York Mellon Corp reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.9% in the first quarter, selling 113,573 shares to hold a position valued at approximately $1.33 billion. While several smaller institutional investors like Anfield Capital and Dogwood Wealth Management increased...

Bullish Signals

  • Q1 EPS beat consensus by $0.38 at $5.15.
  • Revenue grew 5.8% YoY to $8.62 billion.
  • Net margin reached 20.96% with ROE of 137.41%.
  • Full-year 2026 EPS guidance aligns with analyst expectations.
  • BMO reaffirmed 'outperform' rating with $400 price target.

Bearish Signals

  • BNY Mellon reduced stake by 2.9% in Q1.
  • Wall Street Zen downgraded Amgen to 'hold'.
  • Argus lowered price objective from $400 to $375.
  • Stock trades below 200-day moving average of $350.
20
Somewhat Bullish +45

Amgen Inc. $AMGN Position Boosted by Elevation Point Wealth Partners ...

AI-generated analysis

Elevation Point Wealth Partners LLC significantly increased its position in Amgen Inc. (NASDAQ:AMGN) by 91.9% in the first quarter, purchasing an additional 10,271 shares to hold a total of 21,443 shares valued at $7.545 million. Other institutional investors also adjusted their stakes, with Brighton Jones...

Bullish Signals

  • EPS beat estimates at $5.15 vs $4.77 consensus.
  • Revenue grew 5.8% YoY to $8.62 billion.
  • Net margin reached 20.96% with ROE of 137.41%.
  • Investor Elevation Point Wealth increased position by 91.9%.
  • Daiwa Securities maintains 'outperform' rating for long-term optimism.

Bearish Signals

  • Zen downgraded to 'hold' on June 27th.
  • Guggenheim cut target to $340 and rated neutral.
  • SVP Grygiel sold 1,237 shares, dropping ownership 15%.
  • Consensus target of $355.50 exceeds recent insider sale price.